← Eichor
Study identifier: NCT06446128 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)

Condition: Non-Hodgkin Lymphoma, B-cell  ·  Sponsor: Shanghai Cell Therapy Group Co.,Ltd

PhaseEARLY_Phase 1
Planned participants20
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologous chimeric antigen receptor T (CAR-T) cells targeting CD19/CD22/BCMA in patients with relapsed or refractory B cell non-Hodgkin lymphoma.

This description comes directly from the study's public registry record.

Talk to the study team

Jinxing Lou  ·  021-67091399  ·  loujx@shcell.com

Always discuss trial participation with your own doctor first.

Locations (1)

Mengchao Cancer HospitalShanghai, Shanghai Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06446128